Menu

Filters

  • Result Found In

We are your partner in helping you for the upcoming respiratory virus season

We are your partner in helping you for the upcoming respiratory virus season

We are your partner in helping you for the upcoming respiratory virus season

Get your vaccines for the respiratory virus season!

Every year, respiratory viruses affect millions in the United States. It is crucial for health systems and physicians to strategically plan for this respiratory virus season.

Flu in Australia has increased in 2024 from the previous year, which may indicate a strong respiratory virus season is coming to the United States this fall and winter.¹

COVID-19 is also surging in the United States this summer, which is comparable to both 2022 and 2023.²


It is imperative to ensure that your patients stay healthy year round.

We provide top COVID-19, RSV and flu vaccines to help you prepare for the respiratory virus season. Advantages to our offerings include:

Broad offerings from top brands
Best in class cold chain processes and protocol
Easy recall identification

See our portfolio of COVID-19, RSV and flu vaccines today:

Our vaccine portfolio is updated based on availability. Please check back regularly for the latest information.

To further prepare for this respiratory virus season, click here to check out our point-of-care testing portfolio.


¹Source: Australian Government, Australian Respiratory Surveillance Report
²NBC News, Is this the biggest COVID summer wave ever?

*The Moderna COVID-19 Vaccine (2024-2025 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by the FDA, under an Emergency Use Authorization (“EUA”) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months through 11 years of age.
*The Pfizer-BioNTech COVID-19 Vaccine, Monovalent has not been approved or licensed by the FDA, but has been authorized for emergency use by the FDA, under an Emergency Use Authorization (“EUA”) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months of age and older.
*The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) has not been approved or licensed by the FDA, but has been authorized for emergency use by the FDA, under an Emergency Use Authorization (“EUA”) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older.